Royalty Pharma plc has announced that the company has acquired a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from ...

Royalty Pharma announced it has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for US$885 million upfront, with an option to purchase up to an additional US$65 million in ...

Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties, holding interests in over 35 commercial ...

Amid the increasingly competitive myasthenia gravis drug development space, siRNA candidate cemdisiran met phase III endpoints, with the monotherapy showing numerically higher results than a ...

BeOne Medicines revealed it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty ...

BeOne's BRUKINSA leads in liquid cancers, fueling growth with reduced legal risks, strong cash flow, and R&D prospects. Learn ...

To read yesterday’s edition of Five things for pharma marketers to know, click here.

Royalty Pharma will pay up to $950 million for a 7 percent royalty in Amgen’s Imdelltra, a breakthrough small cell lung ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The deal gives Royalty Pharma access to roughly 7% of global net sales of the therapy, Imdelltra, which won U.S. approval ...

Beone Medicines Ltd. (formerly Beigene Ltd.) is selling its worldwide royalty rights on Imdelltra (tarlatamab) sales, ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...